Johnson & Johnson kicked off Q2 2025 pharma earnings season with a bang Wednesday, adding $2 billion to the midpoint of its full-year sales estimate after reporting almost 6% sales growth in the quarter.
Johnson & Johnson kicked off Q2 2025 pharma earnings season with a bang Wednesday, adding $2 billion to the midpoint of its full-year sales estimate after reporting almost 6% sales growth in the quarter.